CLL patients with cytogenetic intermediate/high risk | ||||||
---|---|---|---|---|---|---|
5-mCyt low (n = 20) | 5-mCyt high (n = 10) | Statistics (p) | 5-hmCyt low (n = 23) | 5-hmCyt high (n = 7) | Statistics (p) | |
Age at diagnosis, mean (±SD) | 65.8 (± 10.3) | 65.7 (± 8.0) | NS | 69.6 (± 10.5) | 71.1 (± 7.8) | NS |
Age at study entry, mean (±SD) | 70.3 (± 10.9) | 69.1 (± 7.7) | NS | 69.6 (± 10.9) | 71.1 (± 7.8) | NS |
Binet stage, No. of patients (%) | NS | NS | ||||
A | 8/20 (40%) | 6/10 (60%) | 9/23 (39.1%) | 5/7 (71.4%) | ||
B/C | 12/20 (60%) | 4/10 (40%) | 14/23 (60.9%) | 2/7 (28.6%) | ||
Lymphocytosis (Giga/L), mean (±SD) | 93.5 (± 58.3) | 27.9 (± 22.8) | 0.0008 | 83.7 (± 60.0) | 32.1 (± 26.5) | 0.02 |
IGHV status, No. of patients (%) | NS | NS | ||||
Unmutated (≥ 98% homology) | 4/13 (30.8%) | 1/5 (20%) | 5/15 (33.3%) | 0/5 (0%) | ||
Mutated (< 98% homology) | 9/13 (69.2%) | 4/5 (80%) | 10/15 (66.7%) | 5/5 (100%) | ||
CD38 > 30%, No. of patients (%) | 7/18 (38.9%) | 4/10 (40%) | NS | 7/21 (33.3%) | 4/7 (57.1%) | NS |
LDT from diagnosis, median (months)a | 12 | 24 | 0.04 | 16.5 | 30 | NS |
PFS, median (months)a | 40 | 46 | NS | 40 | 83 | NS |
TFS, median (months)a | 72 | > 120 | NS | 72 | > 120 | NS |